Table 1 CCR5 Antagonists in Clinical Trials
Product | Mechanism of Action | Company | Status |
|---|---|---|---|
Maraviroc | Non-competitive inhibitor | Pfizer | FDA Approved |
Vicriviroc | Non-competitive inhibitor | Schering-Plough | Phase III completed |
Aplaviroc | Non-competitive inhibitor | GlaxoSmithKline | Development discontinued |
INCB009471 | Non-competitive inhibitor | Incyte | Phase I/IIa completed |
TBR 652 | Non-competitive inhibitor | Tobira | Phase II completed |
Pro 140 | Antibody | Progenics | Phase II |
HGS004 | Antibody | Human Genome Sciences | Phase I completed |